76 results on '"Ummanni R"'
Search Results
2. Common recognition principles of B-cell receptor immunoglobulins in CLL and autoimmune disorders: V660
- Author
-
Binder, M., Seismann, H., Wehr, C., Ummanni, R., Balabanov, S., and Trepel, M.
- Published
- 2011
3. A CLL B-cell receptor with stereotypical HCDR3 configuration recognizes the nurse-like cell antigen vimentin which protects CLL cells from apoptosis: V421
- Author
-
Binder, M., Léchenne, B., Ummanni, R., Balabanov, S., and Trepel, M.
- Published
- 2010
4. Erstellung eines Proteinprofils aus Gewebeproben der Prostata
- Author
-
Zimmermann, U., Ummanni, R., Junker, H., Venz, S., Teller, S., Giebel, J., and Walther, R.
- Published
- 2007
- Full Text
- View/download PDF
5. PMA-SiO2 catalyzed synthesis of indolo[2,3-c]quinolines as potent anti cancer agents
- Author
-
Srihari, P., Padmabhavani, B., Ramesh, S., Bharath Kumar, Y., Singh, Ashita, and Ummanni, R.
- Published
- 2015
- Full Text
- View/download PDF
6. Solution NMR structure of ligand free sterol carrier protein 2 like 2 from Aedes aegypti
- Author
-
Singarapu, K.K., primary and Ummanni, R., additional
- Published
- 2017
- Full Text
- View/download PDF
7. Solution NMR structure of palmitated SCP2L2 from Aedes aegypti
- Author
-
Singarapu, K.K., primary and Ummanni, R., additional
- Published
- 2017
- Full Text
- View/download PDF
8. Repurposing of old drugs: Identification of novel sila analogues of rimonabant as potent antitubercular agents
- Author
-
Ramesh, R., primary, Shingare, R., additional, Anand, A., additional, Veeraraghavan, S., additional, Viswanadha, S., additional, Ummanni, R., additional, Gokhale, R., additional, and Reddy, D.S., additional
- Published
- 2016
- Full Text
- View/download PDF
9. Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro
- Author
-
Ummanni, R, Barreto, F, Venz, S, Scharf, C, Barett, C, Mannsperger, H A, Brase, J C, Kuner, R, Schlomm, T, Sauter, G, Sültmann, H, Korf, U, Bokemeyer, C, Walther, R, Brümmendorf, T H, Balabanov, S, University of Zurich, and Balabanov, S
- Subjects
1303 Biochemistry ,10032 Clinic for Oncology and Hematology ,610 Medicine & health ,1600 General Chemistry - Published
- 2012
10. ChemInform Abstract: PMA-SiO2Catalyzed Synthesis of Indolo[2,3-c]quinolines as Potent Anticancer Agents.
- Author
-
Srihari, P., primary, Padmabhavani, B., additional, Ramesh, S., additional, Bharath Kumar, Y., additional, Singh, Ashita, additional, and Ummanni, R., additional
- Published
- 2015
- Full Text
- View/download PDF
11. Mechanical stress enhances CD9 expression in cultured podocytes
- Author
-
Blumenthal, A., primary, Giebel, J., additional, Warsow, G., additional, Li, L., additional, Ummanni, R., additional, Schordan, S., additional, Schordan, E., additional, Klemm, P., additional, Gretz, N., additional, Endlich, K., additional, and Endlich, N., additional
- Published
- 2015
- Full Text
- View/download PDF
12. Mechanical stress enhances CD9 expression in cultured podocytes.
- Author
-
Blumenthal, A., Giebel, J., Warsow, G., Li, L., Ummanni, R., Schordan, S., Schordan, E., Klemm, P., Gretz, N., Endlich, K., and Endlich, N.
- Subjects
KIDNEY disease risk factors ,PROTEIN expression ,TETRASPANIN ,CD9 antigen ,CELL culture ,CELL migration ,PHYSIOLOGICAL stress - Abstract
Elevated glomerular pressure represents a high risk for the development of severe kidney diseases and causes an increase in mechanical load to podocytes. In this study, we investigated whether mechanical stress alters gene expression in cultured podocytes using gene arrays. We found that tetraspanin CD9 is significantly upregulated in cultured podocytes after mechanical stress. The differential expression of CD9 was confirmed by RT-PCR and Western blotting under stretched and unstretched conditions. Furthermore, mechanical stress resulted in a relocalization of CD9. To get an insight into the functional role of CD9, podocytes were transfected with pEGFP-CD9. The expression of CD9 induced the formation of substratum-attached thin arborized protrusions. Ca
2+ depletion revealed that podocytes overexpressing CD9 possess altered adhesive properties in contrast to the control transfected cells. Finally, elevated CD9 expression increased migration of podocytes in a wound assay. In summary, our results suggest that upregulation of CD9 may play an important role in podocyte morphology, adhesion, and migration. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
13. Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation
- Author
-
Meyer-Schwesinger Catherine, Sültmann Holger, Bokemeyer Carsten, Senff Tina, Sauter Guido, Schlomm Thorsten, Barett Christine, Mundt Frederike, Lohmann Frithjof, Braig Melanie, Jost Edgar, Ummanni Ramesh, Brümmendorf Tim H, and Balabanov Stefan
- Subjects
prostate cancer ,UCHL1 ,ubiquitin system ,tumour suppression ,signalling ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background We have previously reported significant downregulation of ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) in prostate cancer (PCa) compared to the surrounding benign tissue. UCHL1 plays an important role in ubiquitin system and different cellular processes such as cell proliferation and differentiation. We now show that the underlying mechanism of UCHL1 downregulation in PCa is linked to its promoter hypermethylation. Furthermore, we present evidences that UCHL1 expression can affect the behavior of prostate cancer cells in different ways. Results Methylation specific PCR analysis results showed a highly methylated promoter region for UCHL1 in 90% (18/20) of tumor tissue compared to 15% (3/20) of normal tissues from PCa patients. Pyrosequencing results confirmed a mean methylation of 41.4% in PCa whereas only 8.6% in normal tissues. To conduct functional analysis of UCHL1 in PCa, UCHL1 is overexpressed in LNCaP cells whose UCHL1 expression is normally suppressed by promoter methylation and found that UCHL1 has the ability to decrease the rate of cell proliferation and suppresses anchorage-independent growth of these cells. In further analysis, we found evidence that exogenous expression of UCHL1 suppress LNCaP cells growth probably via p53-mediated inhibition of Akt/PKB phosphorylation and also via accumulation of p27kip1 a cyclin dependant kinase inhibitor of cell cycle regulating proteins. Notably, we also observed that exogenous expression of UCHL1 induced a senescent phenotype that was detected by using the SA-ß-gal assay and might be due to increased p14ARF, p53, p27kip1 and decreased MDM2. Conclusion From these results, we propose that UCHL1 downregulation via promoter hypermethylation plays an important role in various molecular aspects of PCa biology, such as morphological diversification and regulation of proliferation.
- Published
- 2011
- Full Text
- View/download PDF
14. ChemInform Abstract: PMA-SiO2 Catalyzed Synthesis of Indolo[2,3-c]quinolines as Potent Anticancer Agents.
- Author
-
Srihari, P., Padmabhavani, B., Ramesh, S., Bharath Kumar, Y., Singh, Ashita, and Ummanni, R.
- Published
- 2015
- Full Text
- View/download PDF
15. Prostate cancer-associated autoantibodies in serum against tumor-associated antigens as potential new biomarkers
- Author
-
Simone Venz, Divya Duscharla, Thorsten Schlomm, Ramesh Ummanni, Hans Heinzer, Christine Barett, Stefan Balabanov, Reinhard Walther, Carsten Bokemeyer, Tim H. Brümmendorf, P. V. L. N. Murthy, University of Zurich, and Ummanni, R
- Subjects
Male ,1303 Biochemistry ,Antibodies, Neoplasm ,Biophysics ,610 Medicine & health ,urologic and male genital diseases ,Proteomics ,Biochemistry ,law.invention ,Prostate cancer ,Antigen ,law ,Prostate ,Antigens, Neoplasm ,Biomarkers, Tumor ,Medicine ,Humans ,Autoantibodies ,biology ,business.industry ,Autoantibody ,Cancer ,Prostatic Neoplasms ,medicine.disease ,medicine.anatomical_structure ,10032 Clinic for Oncology and Hematology ,Immunology ,biology.protein ,Recombinant DNA ,Antibody ,business ,1304 Biophysics - Abstract
The limitations of the current prostate cancer (PCa) screening tests demands new biomarkers for early diagnosis of PCa. In this study, we aim to investigate serum autoantibody signatures as PCa specific biomarkers. PCa proteins were resolved by 2-DE and then transferred onto polyvinylidene difluoride membrane, which were subsequently incubated with either pooled serum from PCa patients or from normal controls. Mass spectrometry results have identified 18 antigens from 21 different 2-DE spots associated with PCa. Autoantibody response to antigens PRDX2, PRDX6 and ANXA11 in PCa patient's sera was confirmed using recombinant antigens. Further validation with an independent set of PCa patient's sera have shown relatively increased abundance of PRDX6 and ANXA11 antibodies in PCa patients. Formal concept analysis method was applied to assess whether the abundance of these autoantibodies could influence the classification of patients. However, sensitivity of the single antibody to discriminate prostate tumor and healthy controls varies from 70% to 80%, whereas combination of both PRDX6 and ANXA11 antibodies increased sensitivity to 90% for tumors and 100% for healthy controls. Therefore, we hereby report that the detection of these antibodies in PCa patient's serum in combination with the existing non-invasive diagnostic procedures may have significance in PCa diagnosis. Biological significance The present study aimed to investigate serum autoantibody signatures as new biomarkers for early diagnosis of prostate cancer (PCa). To investigate serum autoantibodies in patients with PCa, we used proteomics approach based on two-dimensional gel electrophoresis (2-DE) and mass spectrometry. Total tissue proteins extracted from prostate were separated by 2-DE and then transferred onto polyvinylidene difluoride (PVDF) membrane, which were subsequently incubated with either pooled serum from PCa patients or from normal controls with no history for PCa. Proteomic analysis results have identified 18 antigens that showed antibody response specifically to cancer patient's serum. For validation experiments using recombinant antigens, confirmed autoantibody response to three antigens PRDX2, PRDX6 and ANXA11. Further validation using a second independent set of PCa patient's sera has shown relatively increased abundance of PRDX6 and ANXA11 antibodies specifically in PCa patients. Partition analysis of patients based on abundance of autoantibodies highlighted a combination of both PRDX6 and ANXA11 antibodies in serum with 90% sensitivity in case of tumors and 100% in case of healthy controls. Therefore, we hereby report that the detection of these antibodies in PCa patient's serum in combination with known markers may have significance in diagnosis of PCa with further validation in larger cohort of samples.
- Published
- 2014
16. Tumor protein D52 (isoform 3) induces NF-κB - STAT3 mediated EMT driving neuroendocrine differentiation of prostate cancer cells.
- Author
-
Sruthi KK, Natani S, and Ummanni R
- Subjects
- Male, Humans, Epithelial-Mesenchymal Transition genetics, Cell Differentiation genetics, Cell Line, Tumor, Protein Isoforms metabolism, Neoplasm Proteins metabolism, STAT3 Transcription Factor genetics, STAT3 Transcription Factor metabolism, NF-kappa B metabolism, Prostatic Neoplasms pathology
- Abstract
In prostate cancer (PCa) patients, a proto-oncogene Tumor protein D52 (TPD52) is overexpressed, and it is involved in different cellular functions. In this study, we report that TPD52 expression is positively associated with the emergence of neuroendocrine PCa (NEPC). With overexpression of TPD52 in LNCaP cells, we found neuroendocrine differentiation (NED) of cells in in-vitro and distinct NED features confirmed by NE markers neuron-specific enolase (NSE) and chromogranin A (CHR-A). Further, we investigated the molecular mechanisms involved in TPD52 mediated NED of PCa cells. We found that TPD52 activates the NF- κB - STAT3 axis for the induction of NED in LNCaP cells. Indeed, inhibition of NF-κB - STAT3 attenuated the progression of NED in TPD52 positive LNCaP cells. Importantly, silencing of TPD52 expression or inhibition of NF-κB - STAT3 activity in a neuroendocrine cell line NCI-H660 showed a marked decrease in the expression of NSE and CHR-A, confirming the reversal of the NE properties. Notably, TPD52 overexpression in LNCaP cells induced expression of N-cadherin, Vimentin, ZEB1, and Snail1 indicating that TPD52 positively regulates epithelial to mesenchymal transition (EMT) of PCa cells towards NED. Moreover, silencing of Snail1 in TPD52 positive cells blocked the progression of NED and, in NCI-H660 cells reversed NE properties as expected. Of the few requirements of TPD52, activation of NF-κB - STAT3 is essential for promoting EMT compelling NED of LNCaP cells. Collectively, these results reveal that TPD52 is associated with the progression of NEPC and emphasizes the need for therapeutic targeting of TPD52 in PCa., Competing Interests: Declaration of Competing Interest The authors declare that there are no conflicts of interest. All the authors reviewed the data, read the manuscript and consented for publication. All the raw data and material is available with the corresponding author., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
17. AMPK targets a proto-oncogene TPD52 (isoform 3) expression and its interaction with LKB1 suppress AMPK-GSK3β signaling axis in prostate cancer.
- Author
-
Khilar P, Sruthi KK, Parveen SMA, Natani S, Jadav SS, and Ummanni R
- Abstract
Tumor protein D52 (TPD52) is a proto-oncogene overexpressed in prostate cancer (PCa) due to gene amplification and it is involved in the cancer progression of many cancers including PCa. However, the molecular mechanisms underlying the role of TPD52 in cancer progression are still under investigation. In this study, we report that the activation of AMP-activated protein kinase (AMPK) by AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide) inhibited the LNCaP and VCaP cells growth by silencing TPD52 expression. Activation of AMPK inhibited the proliferation and migration of LNCaP and VCaP cells. Interestingly, AICAR treatment to LNCaP and VCaP cells led to the downregulation of TPD52 via activation of GSK3β by a decrease of inactive phosphorylation at Ser9. Moreover, in AICAR treated LNCaP cells, inhibition of GSK3β by LiCl attenuated downregulation of TPD52 indicating that AICAR acts via GSK3β. Furthermore, we found that TPD52 interacts with serine/threonine kinase 11 or Liver kinase B1 (LKB1) a known tumor suppressor and an upstream kinase for AMPK. The molecular modeling and MD simulations indicates that the interaction between TPD52 and LKB1 leads to inhibition of the kinase activity of LKB1 as its auto-phosphorylation sites were masked in the complex. Consequently, TPD52-LKB1 interaction may lead to inactivation of AMPK. Moreover, overexpression of TPD52 is found to be responsible for the reduction of pLKB1 (Ser428) and pAMPK (Thr172). Therefore, TPD52 may be playing its oncogenic role via suppressing the AMPK activation. Altogether, our results revealed a new mechanism of PCa progression in which TPD52 overexpression inhibits AMPK activation by interacting with LKB1. These results support that the use of AMPK activators and/or small molecules that could disrupt the TPD52-LKB1 interaction might be useful to suppress PCa cell growth. TPD52 interacts LKB1 and interfere with activation of AMPK in PCa cells., (© 2023. The International CCN Society.)
- Published
- 2023
- Full Text
- View/download PDF
18. Dimethylarginine Dimethylaminohydrolase - 1 expression is increased under tBHP-induced oxidative stress regulates nitric oxide production in PCa cells attenuates mitochondrial ROS-mediated apoptosis.
- Author
-
Asha Parveen SM, Kami Reddy KR, and Ummanni R
- Subjects
- Humans, Male, Antioxidants metabolism, Apoptosis, Arginine metabolism, Proteomics, Reactive Oxygen Species, tert-Butylhydroperoxide pharmacology, Prostatic Neoplasms metabolism, Tumor Cells, Cultured, Amidohydrolases biosynthesis, Amidohydrolases metabolism, Nitric Oxide metabolism, Oxidative Stress, Signal Transduction
- Abstract
Dimethylarginine dimethylaminohydrolase-1 (DDAH1) expression is frequently elevated in different cancers including prostate cancer (PCa) and enhances nitric oxide (NO) production in tumor cells by metabolising endogenous nitric oxide synthase (NOS) inhibitors. DDAH1 protects the PCa cells from cell death and promotes survival. In this study, we have investigated the cytoprotective role of DDAH1 and determined the mechanism of DDAH1 in protecting the cells in tumor microenvironment. Proteomic analysis of PCa cells with stable overexpression of DDAH1 has identified that oxidative stress-related activity is altered. Oxidative stress promotes cancer cell proliferation, survival and causes chemoresistance. A known inducer of oxidative stress, tert-Butyl Hydroperoxide (tBHP) treatment to PCa cells led to elevated DDAH1 level that is actively involved in protecting the PCa cells from oxidative stress induced cell damage. In PC3-DDAH1
- cells, tBHP treatment led to higher mROS levels indicating that the loss of DDAH1 increases the oxidative stress and eventually leads to cell death. Under oxidative stress, nuclear Nrf2 controlled by SIRT1 positively regulates DDAH1 expression in PC3 cells. In PC3-DDAH1+ cells, tBHP induced DNA damage is well tolerated compared to wild-type cells while PC3-DDAH1- became sensitive to tBHP. In PC3 cells, tBHPexposure has increased the production of NO and GSH which may be acting as an antioxidant defence to overcome oxidative stress. Furthermore, in tBHP treated PCa cells, DDAH1 is controlling the expression of Bcl2, active PARP and caspase 3. Taken together, these results confirm that DDAH1 is involved in the antioxidant defence system and promotes cell survival., Competing Interests: Declaration of competing interest The authors declare that there are no conflicts of interest., (Copyright © 2023 Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
19. MicroRNA-147b induces neuroendocrine differentiation of prostate cancer cells by targeting ribosomal protein RPS15A.
- Author
-
Natani S, Ramakrishna M, Nallavolu T, and Ummanni R
- Subjects
- Humans, Male, Androgen Antagonists, Androgens pharmacology, Cell Differentiation, Cell Line, Tumor, Gene Expression Regulation, Neoplastic, Ribosomal Proteins genetics, Ribosomal Proteins metabolism, MicroRNAs genetics, MicroRNAs metabolism, Prostatic Neoplasms pathology
- Abstract
Background: Prostate cancer (PCa) is the leading cause of cancer related deaths in men, often androgen deprivation therapy (ADT) leads to the progression of androgen independent PCa (AIPC) which further leads to Neuroendocrine PCa (NEPC). Identifying the molecular mechanisms which navigate the neuroendocrine differentiation (NED) of PCa cells is clinically relevant. It has been suggested that the micro RNAs (miRNAs) play an important role in the regulation of intrinsic mechanisms relevant to tumor progression, resistance as a result leads to poor prognosis. miR-147b has been transpiring as one of the deregulated miRNAs associated with the occurrence of multiple cancers. The present study has studied the role of miRNA-147b in inducing NEPC., Methods: To investigate the functional role of miR-147b in NEPC, we have expressed miRNA mimics or inhibitors in PCa cells and monitored the progression of NEPC along with PCa cell proliferation and survival. The molecular mechanism miRNA-147b follows was studied using western blot and reverse transcription polymerase chain analysis. miRNA target prediction using bioinformatics tools followed by target validation using luciferase reporter assays was performed., Results: In the present study, we found that miR-147b is highly expressed in AIPC cell lines in particular neuroendocrine cells NCI-H660 and NE-LNCaP derived from LNCaP. Mechanistic studies revealed that overexpression of miR-147b or miRNA mimics induced NED in LNCaP cells in in-vitro while its inhibitor reversed the NE features (increased NE markers and reduced prostate specific antigen) of PC3, NCI-H660 and NE-LNCaP cells. In addition, miR-147b reduced the proliferation rate of LNCaP cells via elevated p27kip1 and lowered cyclin D1 for promoting differentiation. In reporter assays, we have identified ribosomal protein S15A (RPS15A) is a direct target of miRNA-147b and RPS15A expression was negatively regulated by miR-147b in PCa cells. Furthermore, we also report that RPS15A is downregulated in NEPC cells and its expression is inversely correlated with NE markers., Conclusion: Targeting the miR-147b - RPS15A axis may overcome the progression of NEPC and serve as a novel therapeutic target to attenuate NED progression of PCa., (© 2023 Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
20. HIF-1α and Nrf2 regulates hypoxia induced overexpression of DDAH1 through promoter activation in prostate cancer.
- Author
-
Parveen SMA, Natani S, Sruthi K K, Khilar P, and Ummanni R
- Subjects
- Amidohydrolases genetics, Amidohydrolases metabolism, Humans, Male, PC-3 Cells, Promoter Regions, Genetic genetics, Tumor Hypoxia, Hypoxia-Inducible Factor 1, alpha Subunit genetics, Hypoxia-Inducible Factor 1, alpha Subunit metabolism, NF-E2-Related Factor 2 genetics, NF-E2-Related Factor 2 metabolism, Prostatic Neoplasms pathology
- Abstract
Dimethylarginine dimethylaminohydrolase-1 (DDAH1) is overexpressed in prostate cancer (PCa) and promotes PCa progression in in vivo through the ADMA-NO pathway by degrading nitric oxide synthase (NOS) inhibitors such as asymmetric dimethylarginine (ADMA) and monomethylamine arginine (L-NMMA). In this study, we investigated the molecular mechanism involved in the overexpression of DDAH1 in PCa and examined its potential role as a therapeutic target. We observed that DDAH1expression is elevated in PCa (PC3, LNCaP, and DU145) cell lines under hypoxia. ChIP and reporter assay results confirmed that DDAH1 expression is positively regulated by HIF-1α through directly binding to the hypoxia response elements (HRE) located within the promoter region between - 1242/- 1238 upstream of its transcription start site (TSS). Under hypoxia, HIF-1α is translocated into the nucleus and activates its target gene expression in PC3 cells. Interestingly, in the event of HIF-1α inhibition or siRNA-mediated knockdown, an alternative transcription factor Nrf2 promotes DDAH1 expression through antioxidant response elements (AREs) on its promoter. ChIP assay results showed that Nrf2 binds to AREs located between -1016 / -1008 bp from the TSS of DDAH1. Furthermore, knockdown of PCa therapeutic target HSP90, an essential co-factor for both HIF-1α and Nrf2 causes attenuation of hypoxia induced DDAH1 overexpression in PCa cells. These results demonstrate that hypoxia induced upregulation of DDAH1 expression is positively regulated by HIF-1α and Nrf2 in association with HSP90. Therefore, targeting tumor angiogenesis promoting DDAH1 along with standard androgen receptor (AR) targeted therapy may offer an effective strategy to prevent PCa progression., (Copyright © 2022. Published by Elsevier Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
21. Activation of TGF-β - SMAD2 signaling by IL-6 drives neuroendocrine differentiation of prostate cancer through p38MAPK.
- Author
-
Natani S, Sruthi KK, Asha SM, Khilar P, Lakshmi PSV, and Ummanni R
- Subjects
- Androgen Antagonists, Cell Line, Tumor, Humans, Male, Smad2 Protein metabolism, Transforming Growth Factor beta metabolism, p38 Mitogen-Activated Protein Kinases metabolism, Interleukin-6 metabolism, Prostatic Neoplasms genetics
- Abstract
Neuroendocrine prostate cancer (NEPC) is an aggressive, androgen independent PCa and it is detected in patients undergoing androgen deprivation therapy (ADT). Interleukin-6 (IL-6) is a pleiotropic cytokine elevated in PCa patients promotes neuroendocrine differentiation (NED). In this study, PCa cells were differentiated with IL-6 in in-vitro to identify novel targets or signaling pathways associated with emergence of NEPC on deprivation of androgens. From the results, we observed an activation of TGF-β signaling pathway is altered through multiple proteins in differentiated LNCaP cells. Hence, we investigated the role of TGF-β axis in PCa cells differentiation. LNCaP cells treated with IL-6 in androgens deprived media release excess TGF-β ligand and this as conditioned media added to cells stimulated NED of PCa cells. TGF-β released by IL-6 stimulated cells activate p38MAPK through SMAD2 thereby promote NED. Inhibition of TGF-βRI and TGF-βRII signaling activation in LNCaP cells treated with IL-6 did not reversed the NED of cells, possibly due to the reason that the inhibition of TGF-β axis is further activating p38MAPK through SMAD independent manner in PCa cells. However, siRNA mediated knock down or inhibition p38MAPK inactivated TGF-β - SMAD axis in differentiating cells and attenuated NED of LNCaP cells. This result suggests that p38MAPK is the central node for receiving IL-6 signals and promotes NED of LNCaP cells in androgens free media. Remarkably, downregulation or inhibition of p38MAPK in NCI-H660 reversed NED characteristics as well as markers along with inactivation of SMAD2 whereas no effect observed in WPMY-1 normal prostate cells. Taken together these findings unveil that p38MAPK and its upstream regulators are potential targets to overcome the progression of NED of PCa and develop novel therapeutic measures along ADT for effective treatment of PCa., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
22. AMPK/SIRT1 signaling through p38MAPK mediates Interleukin-6 induced neuroendocrine differentiation of LNCaP prostate cancer cells.
- Author
-
Natani S, Dhople VM, Parveen A, Sruthi KK, Khilar P, Bhukya S, and Ummanni R
- Subjects
- Carcinoma, Neuroendocrine pathology, Cell Differentiation, Humans, Male, PC-3 Cells, Prostatic Neoplasms pathology, Signal Transduction, Tumor Cells, Cultured, AMP-Activated Protein Kinases metabolism, Carcinoma, Neuroendocrine metabolism, Interleukin-6 metabolism, Prostatic Neoplasms metabolism, Sirtuin 1 metabolism, p38 Mitogen-Activated Protein Kinases metabolism
- Abstract
Neuroendocrine Prostate Cancer (NEPC) is an aggressive form of androgen independent prostate cancer (AIPC), correlated with therapeutic resistance. Interleukin (IL)-6 promotes proliferation and neuroendocrine differentiation (NED) of androgen dependent LNCaP cells. We treated LNCaP cells with IL-6 and observed for in vitro NED of cells and also expression of NE markers βIII tubulin, neuron-specific enolase (NSE) and chromogranin A (ChA). Here we investigated the proteins and/or pathways involved in NED of LNCaP cells induced by IL-6 and characterized their role in NED of PCa cells. We found that the altered proteins modulated AMPK signaling pathway in NE cells. Remarkably, IL-6 induces NED of LNCaP cells through activation of AMPK and SIRT1 and also both of these are co-regulated while playing a predominant role in NED of LNCaP cells. Of the few requirements of AMPK-SIRT1 activation, increased eNOS is essential for NED by elevating Nitric oxide (NO) levels. Pleiotropic effects of NO ultimately regulate p38MAPK in IL-6 induced NED. Hence, IL-6 induced AMPK-SIRT1 activation eventually transfers its activation signals through p38MAPK for advancing NED of LNCaP cells. Moreover, inactivation of p38MAPK with specific inhibitor (SB203580) attenuated IL-6 induced NED of LNCaP cells. Therefore, IL-6 promotes NED of PCa cells via AMPK/SIRT1/p38MAPK signaling. Finally, targeting AMPK-SIRT1 or p38MAPK in androgen independent PC3 cells with neuroendocrine features reversed their neuroendocrine characteristics. Taken together these novel findings reveal that targeting p38MAPK mitigated NED of PCa cells, and thus it can be a favorable target to overcome progression of NEPC., (Copyright © 2021 Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
23. Investigation on the Anticancer Activity of Symmetric and Unsymmetric Cyclic Sulfamides.
- Author
-
Jun JJ, Duscharla D, Ummanni R, Hanson PR, and Malhotra SV
- Abstract
The sulfamide functional group has been extensively employed in organic synthesis to discover probes and drugs in various applications such as cancer, human immunodeficiency virus (HIV), virus, and diabetes. Herein, we describe the synthesis of 7-membered symmetric and unsymmetric sulfamide compounds and their biological evaluation through the National Cancer Institute (NCI) panel of 60 human tumor cell lines (NCI-60) and the mechanism of action study. The results of a study from the NCI-60 cell line exhibited that many synthesized cyclic sulfamide compounds inhibited breast cancer (MDA-MB-468). The mechanism of action study of a representative compound 18 showed the inhibition of proliferation and apoptosis in A549 lung cancer cells., Competing Interests: The authors declare no competing financial interest., (© 2021 American Chemical Society.)
- Published
- 2021
- Full Text
- View/download PDF
24. N-end rule pathway inhibitor sensitizes cancer cells to antineoplastic agents by regulating XIAP and RAD21 protein expression.
- Author
-
Pore SK, Ganguly A, Sau S, Godeshala S, Kanugula AK, Ummanni R, Kotamraju S, and Banerjee R
- Subjects
- Apoptosis, Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, Cell Cycle Proteins genetics, Cell Proliferation, DNA-Binding Proteins genetics, Drug Resistance, Neoplasm, Drug Synergism, Humans, Neoplasms metabolism, Neoplasms pathology, Tumor Cells, Cultured, Ubiquitin-Protein Ligases genetics, Ubiquitin-Protein Ligases metabolism, X-Linked Inhibitor of Apoptosis Protein genetics, Antineoplastic Agents pharmacology, Cell Cycle Proteins metabolism, DNA-Binding Proteins metabolism, Enzyme Inhibitors pharmacology, Gene Expression Regulation, Neoplastic, Neoplasms drug therapy, Ubiquitin-Protein Ligases antagonists & inhibitors, X-Linked Inhibitor of Apoptosis Protein metabolism
- Abstract
Anticancer drugs exert their effects on cancer cells by deregulating many pathways linked to cell cycle, apoptosis, etc. but cancer cells gradually become resistive against anticancer drugs, thereby necessitating the development of newer generation anticancer molecules. N-end rule pathway has been shown to be involved in the degradation of many cell cycle and apoptosis-related proteins. However, the involvements of this pathway in cancer are not well established. Recently, we developed a non-peptide-based N-end rule pathway inhibitor, RF-C11 for type 1 and 2 recognition domains of E3 ubiquitin ligases. The inhibitor significantly increased the half-life of potential N-degrons leading to significant physiological changes in vivo. We hypothesized RF-C11 may be used to decipher the N-end rule pathway's role in cancer towards the development of anticancer therapeutics. In this study, we showed that RF-C11, barring noncancer cells, significantly sensitizes cancer cells towards different anticancer agents tested. We further find that the profound cellular sensitization to anticancer drugs was affected by (a) downregulation of X-linked inhibitor of apoptosis protein, an antiapoptotic protein and (b) by stabilization of RAD21, and thereby inhibiting metaphase to anaphase promotion. The study shows that RF-C11 or its analogs may be used as a novel additive in combination therapy against cancer., (© 2019 Wiley Periodicals, Inc.)
- Published
- 2020
- Full Text
- View/download PDF
25. Synthesis and evaluation of a novel quinoline-triazole analogs for antitubercular properties via molecular hybridization approach.
- Author
-
Ramprasad J, Kumar Sthalam V, Linga Murthy Thampunuri R, Bhukya S, Ummanni R, Balasubramanian S, and Pabbaraja S
- Subjects
- Antitubercular Agents pharmacology, Cell Line, Tumor, Cell Survival drug effects, Click Chemistry, Crystallization, Drug Evaluation, Preclinical, HEK293 Cells, Humans, Microbial Sensitivity Tests, Molecular Structure, Nucleic Acid Hybridization, Structure-Activity Relationship, Triazoles pharmacology, Antitubercular Agents chemical synthesis, Mycobacterium tuberculosis drug effects, Quinolines chemistry, Triazoles chemical synthesis
- Abstract
Towards a quest for establishing new antitubercular agents, we have designed new quinoline-triazole hybrid analogs in a six-step reaction sequence involving versatile reactions like Vilsmeier-Haack and click reaction protocol. The design is based on the structural modification of bedaquiline moiety and involves molecular hybridization approach. The structure of the synthesized product was elucidated by single crystal X-ray diffraction study. The synthesized target compounds were screened for their antitubercular activity against Mycobacterium bovis. Interestingly, two compounds of the series (8d and 8m) showed significant inhibition with MIC of 31.5 and 34.8 μM. Compounds bearing 3-fluoro phenyl and n-octyl groups on the 1,2,3-triazole ring emerged as the most potent leads among the compounds tested. Further these hit compounds were also screened for their cytotoxic effect on human embryonic kindey 293 (HEK293) cells and other cancer cell lines such as HeLa (Cervical), PC3 (Prostate), Panc-1 (Pancreatic) and SKOV3 (Ovarian) indicating to be safer with the minimal cytotoxicity., (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
26. Tumor protein D52 (isoform 3) interacts with and promotes peroxidase activity of Peroxiredoxin 1 in prostate cancer cells implicated in cell growth and migration.
- Author
-
Dasari C, Reddy KRK, Natani S, Murthy TRL, Bhukya S, and Ummanni R
- Subjects
- Down-Regulation, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Humans, Male, Neoplasm Proteins genetics, PC-3 Cells, Peroxiredoxins genetics, Prostatic Neoplasms genetics, Prostatic Neoplasms pathology, Protein Domains, Proto-Oncogene Mas, Cell Movement, Cell Proliferation, Neoplasm Proteins metabolism, Peroxiredoxins biosynthesis, Prostatic Neoplasms metabolism, Protein Multimerization
- Abstract
Tumor protein D52 (TPD52) is overexpressed in multiple cancers including prostate cancer due to gene amplification and investigations to understand its role in the pathophysiology of different cancers are continuing. GST pull-down assays and Tandem affinity purification of TPD52 as bait identified novel prey Peroxiredoxin 1 (PRDX1) in prostate cancer (PCa) cells. PRDX1 interaction with TPD52 was confirmed in immunoprecipitation and affinity interaction assays. Mapping of interaction domain indicated that PRDX1 interacts with C-terminal region of TPD52 containing PEST domain between 152 and 179 amino acids, a new binding region of TPD52. Here we show that TPD52 interaction with PRDX1 increased its peroxidase activity and ectopic expression of TPD52 induced dimerization of PRDX1 in PCa cells. Moreover, H
2 O2 exposure evoked the interaction between TPD52 and PRDX1 while depletion of both proteins led to the accumulation of H2 O2 suggesting peroxidase activity is important to maintain oxidative capacity in PCa cells. We also observed that overexpression or downregulation of TPD52 and PRDX1 individually or together affecting PCa cells growth, survival, and migration. Altogether, our results show a novel interaction partner of TPD52 providing new insights of its functions and ascertain the role of TPD52-PRDX1 interaction in PCa progression., (Copyright © 2019 Elsevier B.V. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
27. Novel Cellularly Active Inhibitor Regresses DDAH1 Induced Prostate Tumor Growth by Restraining Tumor Angiogenesis through Targeting DDAH1/ADMA/NOS Pathway.
- Author
-
Kami Reddy KR, Dasari C, Vandavasi S, Natani S, Supriya B, Jadav SS, Sai Ram N, Kumar JM, and Ummanni R
- Subjects
- Animals, Antineoplastic Agents chemistry, Antineoplastic Agents metabolism, Arginine metabolism, Cell Line, Tumor, Cell Proliferation drug effects, Cell Survival drug effects, Chemokines metabolism, DNA-Binding Proteins metabolism, Drug Screening Assays, Antitumor, Enzyme Inhibitors chemistry, Enzyme Inhibitors metabolism, Gene Expression Regulation drug effects, Humans, Hypoxia-Inducible Factor 1, alpha Subunit metabolism, Male, Mice, Nude, Molecular Docking Simulation, Nitric Oxide metabolism, Nitric Oxide Synthase Type II metabolism, Prostatic Neoplasms blood supply, Prostatic Neoplasms metabolism, Prostatic Neoplasms pathology, Pyridines chemistry, Pyridines metabolism, Signal Transduction, Transcription Factors metabolism, Vascular Endothelial Growth Factor A metabolism, Amidohydrolases antagonists & inhibitors, Antineoplastic Agents therapeutic use, Arginine analogs & derivatives, Enzyme Inhibitors therapeutic use, Neovascularization, Pathologic drug therapy, Prostatic Neoplasms drug therapy, Pyridines therapeutic use
- Abstract
Dimethylarginine dimethylaminohydrolase1 (DDAH1) inhibitors are important therapeutics by virtue of their ability to control nitric oxide (NO) production by elevating asymmetric dimethylarginine (ADMA) levels. In a screening campaign, we identified that DD1E5 (3-amino-6- tert-butyl-N-(1,3-thiazol-2-yl)-4-(trifluoromethyl)thieno[2,3- b]pyridine-2- carboxamide) inhibits the DDAH1 activity both in vitro and in cultured cells. Mechanistic studies found that DD1E5 is a competitive inhibitor (dissociation constant ( K
i ) of 2.05 ± 0.15 μM). Enzyme kinetic assays showed time and concentration dependent inhibition of DDAH1 with DD1E5, which shows tight binding with an inactivation rate constant of 0.2756 ± 0.015 M-1 S-1 . Treatment of cancer cells with DDAH1 inhibitors shows inhibition of cell proliferation and a subsequent decrease in NO production with ADMA accumulation. DD1E5 reversed the elevated VEGF, c-Myc, HIF-1α, and iNOS levels induced by exogenous DDAH1 overexpression in PCa cells. Moreover, DD1E5 significantly increased intracellular levels of ADMA and reduced NO production, suggesting its therapeutic potential for cancers in which DDAH1 is upregulated. In in vitro assays, DD1E5 abrogated the secretion of angiogenic factors (bFGF and IL-8) into conditional media, indicating its antiangiogenic potential. DD1E5 inhibited in vivo growth of xenograft tumors derived from PCa cells with DDAH1 overexpression, by reducing tumor endothelial content represented with low CD31 expression. VEGF, HIF-1α, and iNOS expression were reversed in DD1E5 treated tumors compared to respective control tumors. In this work, integrating multiple approaches shows DD1E5 is a promising tool for the study of methylarginine-mediated NO control and a potential therapeutic lead compound against pathological conditions with elevated NO production such as cancers and other diseases.- Published
- 2019
- Full Text
- View/download PDF
28. Corticosteroids protect infected cells against mycobacterial killing in vitro.
- Author
-
Tükenmez H, Edström I, Kalsum S, Braian C, Ummanni R, Fick SB, Sundin C, Lerm M, Elofsson M, and Larsson C
- Subjects
- Antitubercular Agents pharmacology, Cell Line, Cell Survival drug effects, Cells, Cultured, Fibroblasts cytology, Fibroblasts metabolism, Fibroblasts microbiology, Humans, Macrophages cytology, Macrophages metabolism, Macrophages microbiology, Mycobacterium tuberculosis drug effects, Receptors, Glucocorticoid metabolism, Tuberculosis metabolism, Tuberculosis microbiology, Adrenal Cortex Hormones pharmacology, Fibroblasts drug effects, Macrophages drug effects, Protective Agents pharmacology, Tuberculosis drug therapy
- Abstract
The effect of corticosteroids on human physiology is complex and their use in tuberculosis patients remains controversial. In a high-throughput screening approach designed to discover virulence inhibitors, several corticosteroids were found to prevent cytolysis of fibroblasts infected with mycobacteria. Further experiments with Mycobacterium tuberculosis showed anti-cytolytic activity in the 10 nM range, but no effect on bacterial growth or survival in the absence of host cells at 20 μM. The results from a panel of corticosteroids with various affinities to the glucocorticoid- and mineralocorticoid receptors indicate that the inhibition of cytolysis most likely is mediated through the glucocorticoid receptor. Using live-imaging of M. tuberculosis-infected human monocyte-derived macrophages, we also show that corticosteroids to some extent control intracellular bacteria. In vitro systems with reduced complexity are to further study and understand the interactions between bacterial infection, immune defense and cell signaling., (Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
29. Mycobacterium tuberculosis virulence inhibitors discovered by Mycobacterium marinum high-throughput screening.
- Author
-
Tükenmez H, Edström I, Ummanni R, Fick SB, Sundin C, Elofsson M, and Larsson C
- Subjects
- Cell Survival, Fibroblasts physiology, High-Throughput Screening Assays methods, Virulence, Anti-Bacterial Agents isolation & purification, Mycobacterium marinum drug effects, Mycobacterium marinum pathogenicity, Virulence Factors antagonists & inhibitors
- Abstract
High-throughput screening facilities do not generally support biosafety level 3 organisms such as Mycobacterium tuberculosis. To discover not only antibacterials, but also virulence inhibitors with either bacterial or host cell targets, an assay monitoring lung fibroblast survival upon infection was developed and optimized for 384-plate format and robotic liquid handling. By using Mycobacterium marinum as surrogate organism, 28,000 compounds were screened at biosafety level 2 classification, resulting in 49 primary hits. Exclusion of substances with unfavourable properties and known antimicrobials resulted in 11 validated hits of which 7 had virulence inhibiting properties and one had bactericidal effect also in wild type Mycobacterium tuberculosis. This strategy to discover virulence inhibitors using a model organism in high-throughput screening can be a valuable tool for other researchers working on drug discovery against tuberculosis and other biosafety level 3 infectious agents.
- Published
- 2019
- Full Text
- View/download PDF
30. Interleukin-6 induced overexpression of valosin-containing protein (VCP)/p97 is associated with androgen-independent prostate cancer (AIPC) progression.
- Author
-
Duscharla D, Reddy Kami Reddy K, Dasari C, Bhukya S, and Ummanni R
- Subjects
- Androgen Antagonists pharmacology, Cell Cycle Checkpoints drug effects, Cell Line, Tumor, Cell Proliferation drug effects, Disease Progression, Humans, Male, Prostatic Neoplasms, Castration-Resistant genetics, Prostatic Neoplasms, Castration-Resistant metabolism, Receptors, Androgen drug effects, Receptors, Androgen metabolism, STAT3 Transcription Factor drug effects, STAT3 Transcription Factor metabolism, Vimentin metabolism, Gene Expression Regulation, Neoplastic drug effects, Interleukin-6 pharmacology, Prostatic Neoplasms, Castration-Resistant drug therapy, Valosin Containing Protein drug effects
- Abstract
Though Androgen deprivation therapy (ADT) is effective initially, numerous patients become resistant to it and develop castration resistant PCa (CRPC). Cytokines promotes ligand independent activation of AR. Interleukin-6 (IL-6) levels are elevated in CRPC patients and regulate AR activity. However, progression to CRPC is not fully understood. In this study, we analyzed differential protein expression in LNCaP cells treated with IL-6 using proteomics. Results revealed altered expression of 27 proteins and Valosin-containing protein (VCP)/p97 plays a predominant role in co-regulation of altered proteins. Interestingly, IL-6 induced VCP expression through Pim-1 via STAT3 is AR independent there by suggesting a role for VCP in CRPC. Transfection of LNCaP cells for VCP overexpression showed an increased cell proliferation, migration, and invasion where as its inhibition by NMS-873 showed the reverse effect causing cell death. Mechanistic studies demonstrate that cell death occurs due to apoptosis by endoplasmic reticulum (ER) stress, elevated cell cycle inhibitors p21, p27kip1, and active PARP and reduced Bcl-2. VCP promotes cell invasion and migration by altering E-cadherin and Vimentin levels inversely triggering EMT of PCa cells. VCP immunostaining revealed no staining in BPH but strong staining in PCa. This study determines VCP may play an important role in progression to CRPC and it can be a favorable target with to develop new therapies to treat ADT resistant prostate cancer., (© 2018 Wiley Periodicals, Inc.)
- Published
- 2018
- Full Text
- View/download PDF
31. Dimethylarginine dimethylaminohydrolase-1 (DDAH1) is frequently upregulated in prostate cancer, and its overexpression conveys tumor growth and angiogenesis by metabolizing asymmetric dimethylarginine (ADMA).
- Author
-
Reddy KRK, Dasari C, Duscharla D, Supriya B, Ram NS, Surekha MV, Kumar JM, and Ummanni R
- Subjects
- Animals, Arginine genetics, Arginine metabolism, Cell Movement genetics, Cell Proliferation genetics, Fibroblast Growth Factor 2 genetics, Fibroblast Growth Factor 2 metabolism, Heterografts metabolism, Heterografts pathology, Humans, Hypoxia-Inducible Factor 1, alpha Subunit genetics, Hypoxia-Inducible Factor 1, alpha Subunit metabolism, Interleukin-8 genetics, Interleukin-8 metabolism, Male, Mice, Mice, Nude, Neoplasm Invasiveness genetics, Neoplasm Invasiveness physiopathology, Neoplasm Proteins genetics, Neoplasm Proteins metabolism, Neoplasm Transplantation, Nitric Oxide genetics, Nitric Oxide metabolism, Nitric Oxide Synthase Type II genetics, Nitric Oxide Synthase Type II metabolism, PC-3 Cells, Platelet Endothelial Cell Adhesion Molecule-1 immunology, Platelet Endothelial Cell Adhesion Molecule-1 metabolism, Prostatic Neoplasms genetics, Prostatic Neoplasms pathology, Signal Transduction, Vascular Endothelial Growth Factor A genetics, Vascular Endothelial Growth Factor A metabolism, Amidohydrolases genetics, Amidohydrolases metabolism, Arginine analogs & derivatives, Gene Expression Regulation, Neoplastic, Neovascularization, Pathologic genetics, Neovascularization, Pathologic metabolism, Prostatic Neoplasms metabolism, Up-Regulation
- Abstract
Tissue microarray analysis confirmed higher dimethylarginine dimethylaminohydrolase-1 (DDAH1) expression in prostate cancer (PCa) compared to benign and normal prostate tissues. DDAH1 regulates nitric oxide (NO) production by degrading endogenous nitric oxide synthase (NOS) inhibitor, asymmetric dimethylarginine (ADMA). This study examined whether DDAH1 has any physiological role in PCa progression. Using overexpression of DDAH1 in PCa (PC3 and LNCaP) cell lines, we found that DDAH1 promotes cell proliferation, migration and invasion by lowering ADMA levels, as well as increasing NO production. VEGF, HIF-1α and iNOS were upregulated in DDAH1 expressing cells as result of elevated NO. DDAH1 increased secretion of pro-angiogenic signals bFGF and IL-8, into conditioned media. Treatment of DDAH1-positive PCa cells with NOS inhibitors (L-NAME and 1400 W) attenuated DDAH1 activity to promote cell growth. Xenografts derived from these cells grew significantly faster (> twofold) than those derived from control cells. Proliferation rate of cells stably expressing mutant DDAH1 was same as control cells unlike wild-type DDAH1-positive PCa cells. Xenograft tumors derived from mutant-positive cells did not differ from control tumors. VEGF, HIF-1α and iNOS expression did not differ in DDAH1 mutant-positive tumors compared to control tumors, but was upregulated in wild-type DDAH1 overexpressing tumors. Furthermore, CD31 immunostaining on xenograft tissues demonstrated that DDAH1 tumors had high endothelial content than mutant DDAH1 tumors. These data suggest that DDAH1 is an important mediator of PCa progression and NO/DDAH pathway needs to be considered in developing therapeutic strategies targeted at PCa.
- Published
- 2018
- Full Text
- View/download PDF
32. One-Pot Synthesis of Triazolo-Heterolignans: Biological Evaluation and Molecular Docking Studies as Tubulin Inhibitors.
- Author
-
Reddy CR, Subbarao M, Vijaykumar J, Jadav SS, Sasane N, Valleti RR, Supriya B, and Ummanni R
- Subjects
- Antineoplastic Agents chemical synthesis, Antineoplastic Agents chemistry, Cell Proliferation drug effects, Dose-Response Relationship, Drug, Drug Screening Assays, Antitumor, Humans, Lignans chemistry, Molecular Structure, Structure-Activity Relationship, Triazoles chemistry, Tumor Cells, Cultured, Antineoplastic Agents pharmacology, Lignans pharmacology, Molecular Docking Simulation, Triazoles pharmacology, Tubulin metabolism
- Abstract
Background: The anti-mitotic activity of podophyllotoxin derivative targeting tubulin enzyme proved them as strong polymerization inhibitors. The introduction of heteroatom along with different heteroaryl systems in naturally obtained lignans created a latitude for design of bioactive components. A novel one-pot sequential propargylation/cycloaddition reaction strategy has been followed to synthesize triazolo-heterolignans., Objective: To screen anti-proliferative activity of novel heterolignans and to determine their mode of action., Method: SRB assay, Cytotoxicity evaluation, PI uptake for analysis of cell cycle, caspase-3 activity, Western blot analysis and Immunofluorescence and molecular docking studies., Results: SRB assay of synthesised compounds were provided compound 3a and 5f to be highly active among the synthesized compounds. The Compound 3a showed cell cycle arrest at G2/M phase and 5f arrest the cells at G1 phase. Compound 5f displayed caspase 3 mediated apoptotic effect at lower levels. Compound 3a and 5f displayed microtubule disassembly inhibition same as paclitaxel and found to be occupying colchicine binding site of tubulin, both ligands were depicted π-cation interaction with Lys352 residue and triazole ring accommodated at the lactone binding site., Conclusion: A novel one-pot sequential propargylation/cycloaddition reaction has been developed for the synthesis of triazolo-heterolignans. Compound 3a and 5f were displayed good cytotoxic activities and found to inhibit microtubule disassembly. The importance of triazole ring of heterolignans has been studied by molecular docking experiments and results were compared., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2018
- Full Text
- View/download PDF
33. All-Trans-Retinoic Acid Stimulates Overexpression of Tumor Protein D52 (TPD52, Isoform 3) and Neuronal Differentiation of IMR-32 Cells.
- Author
-
Kotapalli SS, Dasari C, Duscharla D, Kami Reddy KR, Kasula M, and Ummanni R
- Subjects
- Antigens, Differentiation biosynthesis, Cell Line, Tumor, Humans, Protein Isoforms biosynthesis, Proto-Oncogene Mas, Cell Differentiation drug effects, Neoplasm Proteins biosynthesis, Neurons metabolism, Signal Transduction drug effects, Tretinoin pharmacology
- Abstract
Tumor protein D52 (TPD52), a proto-oncogene is overexpressed in a variety of epithelial carcinomas and plays an important role in cell proliferation, migration, and cell death. In the present study we found that the treatment of IMR-32 neuroblastoma (NB) cells with retinoic acid (RA) stimulates an increase in expression of TPD52. TPD52 expression is detectable after 72 h, can be maintained till differentiation of NB cells suggesting that TPD52 is involved in differentiation. Here, we demonstrate that TPD52 is essential for RA to promote differentiation of NB cells. Our results show that exogenous expression of EGFP-TPD52 in IMR-32 cells resulted cell differentiation even without RA. RA by itself and with overexpression of TPD52 can increase the ability of NB cells differentiation. Interestingly, transfection of IMR-32 cells with a specific small hairpin RNA for efficient knockdown of TPD52 attenuated RA induced NB cells differentiation. Transcriptional and translational level expression of neurotropic (BDNF, NGF, Nestin) and differentiation (β III tubulin, NSE, TH) factors in NB cells with altered TPD52 expression and/or RA treatment confirmed essential function of TPD52 in cellular differentiation. Furthermore, we show that TPD52 protects cells from apoptosis and arrest cell proliferation by varying expression of p27Kip1, activation of Akt and ERK1/2 thus promoting cell differentiation. Additionally, inhibition of STAT3 activation by its specific inhibitor arrested NB cells differentiation by EGFP-TPD52 overexpression with or without RA. Taken together, our data reveal that TPD52 act through activation of JAK/STAT signaling pathway to undertake NB cells differentiation induced by RA. J. Cell. Biochem. 118: 4358-4369, 2017. © 2017 Wiley Periodicals, Inc., (© 2017 Wiley Periodicals, Inc.)
- Published
- 2017
- Full Text
- View/download PDF
34. "Click" reaction based synthesis of nimbolide derivatives and study of their insect antifeedant activity against Spodoptera litura Larvae.
- Author
-
Siva B, Devi A, Venkanna A, Poornima B, Sukumar G, Reddy SD, Vijaya M, Ummanni R, and Babu KS
- Subjects
- Animals, Larva, Molecular Structure, Click Chemistry, Insecticides chemical synthesis, Limonins chemical synthesis, Spodoptera, Triazoles chemical synthesis
- Abstract
A series of Nimbolide-triazole conjugates were synthesized through copper(I)- catalyzed azide-alkyne "click" chemistry approach and these derivatives (2-4, 2a-2l) were characterized using modern spectroscopic techniques. Antifeedant activities of these derivatives were studied on Tobacco Caterpillar, Spodoptera litura (F.) using no-choice leaf disk bioassay. Interestingly, the synthesized derivatives were more effective in reducing feedancy by insect species when compared to the parent nimbolide. Among the tested compounds, 2a, 2c, and 2d showed potent antifeedancy with ED
50 values of 0.49, 0.95 and 0.97mg/cm2 against S. litura. Several of the analogs were also toxic or caused developmental abnormalities following leaf disc assay., (Copyright © 2017 Elsevier B.V. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
35. Epigenetic suppression of human telomerase ( hTERT ) is mediated by the metastasis suppressor NME2 in a G-quadruplex-dependent fashion.
- Author
-
Saha D, Singh A, Hussain T, Srivastava V, Sengupta S, Kar A, Dhapola P, Dhople V, Ummanni R, and Chowdhury S
- Subjects
- Amino Acid Substitution, Carcinoma enzymology, Carcinoma pathology, Cell Line, Tumor, Cells, Cultured, Chromatin Immunoprecipitation, Fibrosarcoma enzymology, Fibrosarcoma pathology, Genes, Reporter, Histone Demethylases chemistry, Histone Demethylases metabolism, Humans, Mutagenesis, Site-Directed, NM23 Nucleoside Diphosphate Kinases antagonists & inhibitors, NM23 Nucleoside Diphosphate Kinases chemistry, NM23 Nucleoside Diphosphate Kinases genetics, Neoplasm Proteins antagonists & inhibitors, Neoplasm Proteins chemistry, Neoplasm Proteins genetics, Neoplasm Proteins metabolism, Point Mutation, Protein Multimerization, RNA Interference, Recombinant Proteins chemistry, Recombinant Proteins metabolism, Repressor Proteins antagonists & inhibitors, Repressor Proteins chemistry, Repressor Proteins genetics, Repressor Proteins metabolism, Telomerase antagonists & inhibitors, Telomerase genetics, Carcinoma metabolism, Epigenetic Repression, Fibrosarcoma metabolism, G-Quadruplexes, NM23 Nucleoside Diphosphate Kinases metabolism, Promoter Regions, Genetic, Telomerase metabolism
- Abstract
Transcriptional activation of the human telomerase reverse transcriptase ( hTERT ) gene, which remains repressed in adult somatic cells, is critical during tumorigenesis. Several transcription factors and the epigenetic state of the hTERT promoter are known to be important for tight control of hTERT in normal tissues, but the molecular mechanisms leading to hTERT reactivation in cancer are not well-understood. Surprisingly, here we found occupancy of the metastasis suppressor non-metastatic 2 (NME2) within the hTERT core promoter in HT1080 fibrosarcoma cells and HCT116 colon cancer cells and NME2-mediated transcriptional repression of hTERT in these cells. We also report that loss of NME2 results in up-regulated hTERT expression. Mechanistically, additional results indicated that the RE1-silencing transcription factor (REST)-lysine-specific histone demethylase 1 (LSD1) co-repressor complex associates with the hTERT promoter in an NME2-dependent way and that this assembly is required for maintaining repressive chromatin at the hTERT promoter. Interestingly, a G-quadruplex motif at the hTERT promoter was essential for occupancy of NME2 and the REST repressor complex on the hTERT promoter. In light of this mechanistic insight, we studied the effects of G-quadruplex-binding ligands on hTERT expression and observed that several of these ligands repressed hTERT expression. Together, our results support a mechanism of hTERT epigenetic control involving a G-quadruplex promoter motif, which potentially can be targeted by tailored small molecules., (© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.)
- Published
- 2017
- Full Text
- View/download PDF
36. Tumor protein D52 (isoform 3) contributes to prostate cancer cell growth via targeting nuclear factor-κB transactivation in LNCaP cells.
- Author
-
Dasari C, Yaghnam DP, Walther R, and Ummanni R
- Subjects
- Apoptosis genetics, Cell Proliferation genetics, Gene Expression Regulation, Neoplastic, Humans, Male, Neoplasm Proteins genetics, Oncogene Protein v-akt genetics, Oncogene Protein v-akt metabolism, Prostatic Neoplasms pathology, Protein Isoforms genetics, Proto-Oncogene Mas, RNA, Small Interfering genetics, STAT3 Transcription Factor metabolism, Transcription Factor RelA metabolism, Transfection, Neoplasm Proteins biosynthesis, Prostatic Neoplasms genetics, STAT3 Transcription Factor genetics, Transcription Factor RelA genetics
- Abstract
Our previous study showed that TPD52 overexpression could increase migration and proliferation of LNCaP cells contributing to the development of prostate cancer. However, mechanism of TPD52 in prostate cancer initiation and progression remains elusive. In this study, we investigated the possible underlying mechanism of TPD52 in prostate cancer progression. In LNCaP cells, TPD52 expression was altered by transfecting with either EGFP-TPD52 or specific short hairpin RNA. Overexpression of TPD52 protected LNCaP cells from apoptosis through elevated anti-apoptotic proteins XIAP, Bcl-2, and Cyclin D1, whereas Bax was downregulated. Mechanistically, we found that TPD52 confers transactivation of nuclear factor-κB, thereby enhancing its target gene expression in LNCaP cells. TPD52 promotes LNCaP cell invasion probably via increased matrix metalloproteinase 9 expression and its activity while tissue inhibitor of metalloproteinase expression is significantly downregulated. Notably, TPD52 might be involved in cell adhesion, promoting tumor metastasis by inducing loss of E-cadherin, expression of vimentin and vascular cell adhesion molecule, and additionally activation of focal adhesion kinase. Furthermore, TPD52 directly interacts with nuclear factor-κB p65 (RelA) and promotes accumulation of phosphorylated nuclear factor-κB (p65)
S536 that is directly linked with nuclear factor-κB transactivation. Indeed, depletion of TPD52 or inhibition of nuclear factor-κB in TPD52-positive cells inhibited secretion of tumor-related cytokines and contributes to the activation of STAT3, nuclear factor-κB, and Akt. Interestingly, in TPD52 overexpressing LNCaP cells, nuclear factor-κB inhibition prevented the autocrine/paracrine activation of STAT3. TPD52 activates STAT3 through ascertaining a cross talk between the nuclear factor-κB and the STAT3 signaling systems. Collectively, these results reveal mechanism by which TPD52 is associated with prostate cancer progression and highlight the approach for therapeutic targeting of TPD52 in prostate cancer.- Published
- 2017
- Full Text
- View/download PDF
37. Expanding the tetrahydroquinoline pharmacophore.
- Author
-
Goli N, Mainkar PS, Kotapalli SS, K T, Ummanni R, and Chandrasekhar S
- Subjects
- Animals, Antineoplastic Agents chemical synthesis, Antineoplastic Agents chemistry, Antineoplastic Agents pharmacology, Antitubercular Agents chemical synthesis, Antitubercular Agents chemistry, Antitubercular Agents pharmacology, Cattle, Cell Line, Tumor, Cycloaddition Reaction, Drug Discovery, Humans, Mycobacterium bovis drug effects, Neurogenesis drug effects, Quinolines chemical synthesis, Small Molecule Libraries chemical synthesis, Tuberculosis, Bovine drug therapy, Tuberculosis, Bovine microbiology, Quinolines chemistry, Quinolines pharmacology, Small Molecule Libraries chemistry, Small Molecule Libraries pharmacology
- Abstract
Tetrahydroquinoline is a privileged scaffold with a large number of biological applications. The tetrahydroquinoline pharmacophore has been expanded to yield 34 compounds. Biological screening of these compounds led to the identification of tetrahydroquinoline as neurotropic agents not reported earlier., (Copyright © 2017 Elsevier Ltd. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
38. Repurposing of a drug scaffold: Identification of novel sila analogues of rimonabant as potent antitubercular agents.
- Author
-
Ramesh R, Shingare RD, Kumar V, Anand A, B S, Veeraraghavan S, Viswanadha S, Ummanni R, Gokhale R, and Srinivasa Reddy D
- Subjects
- Antitubercular Agents metabolism, Antitubercular Agents toxicity, Hep G2 Cells, Humans, Microbial Sensitivity Tests, Models, Molecular, Molecular Conformation, Mycobacterium tuberculosis drug effects, Piperidines metabolism, Piperidines toxicity, Pyrazoles metabolism, Pyrazoles toxicity, Rimonabant, Structure-Activity Relationship, Antitubercular Agents chemistry, Antitubercular Agents pharmacology, Drug Repositioning, Piperidines chemistry, Piperidines pharmacology, Pyrazoles chemistry, Pyrazoles pharmacology
- Abstract
The structural similarity between an MmpL3 inhibitor BM212, and a cannabinoid receptor modulator rimonabant, prompted us to investigate the anti-tubercular activity of rimonabant and its analogues. Further optimization, particularly through incorporation of silicon into the scaffold, resulted in new compounds with significant improvement in anti-tubercular activity against Mycobacterium tuberculosis (H37Rv). The sila analogue 18a was found to be the most potent antimycobacterial compound (MIC, 31 ng/mL) from this series with an excellent selectivity index., (Copyright © 2016 Elsevier Masson SAS. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
39. Solution Nuclear Magnetic Resonance Studies of Sterol Carrier Protein 2 Like 2 (SCP2L2) Reveal the Insecticide Specific Structural Characteristics of SCP2 Proteins in Aedes aegypti Mosquitoes.
- Author
-
Singarapu KK, Ahuja A, Potula PR, and Ummanni R
- Subjects
- Animals, Insecticides chemistry, Protein Conformation, Aedes chemistry, Carrier Proteins chemistry, Insect Proteins chemistry, Nuclear Magnetic Resonance, Biomolecular methods
- Abstract
Sterol carrier protein 2 like 2 from Aedes aegypti (AeSCP2L2) plays an important role in lipid transport in mosquitoes for its routine metabolic processes. Repeated unsuccessful attempts to crystallize ligand free SCP2L2 prompted us to undertake nuclear magnetic resonance (NMR) spectroscopy to determine its three-dimensional structure. We report here the three-dimensional structures and dynamics of apo-AeSCP2L2 and its complex with palmitate. The (15)N heteronuclear single-quantum coherence spectrum of apo-AeSCP2L2 displayed multiple peaks for some of the amide resonances, implying the presence of multiple conformations in solution, which are transformed to a single conformation upon formation of the complex with plamitate. The three-dimensional structures of apo-AeSCP2L2 and palmitated AeSCP2L2 reveal an α/β mixed fold, with five β-strands and four α-helices, very similar to the other SCP2 protein structures. Unlike the crystal structure of palmitated AeSCP2L2, both solution structures are monomeric. It is further confirmed by the rotational correlation times determined by NMR relaxation times (T1 and T2) of the amide protons. In addition, the palmitated AeSCP2L2 structure contains two palmitate ligands, bound in the binding pocket, unlike the three palmitates bound in the dimeric form of AeSCP2L2 in the crystals. The relaxation experiments revealed that complex formation significantly reduces the dynamics of the protein in solution.
- Published
- 2016
- Full Text
- View/download PDF
40. Prostate Cancer Associated Lipid Signatures in Serum Studied by ESI-Tandem Mass Spectrometryas Potential New Biomarkers.
- Author
-
Duscharla D, Bhumireddy SR, Lakshetti S, Pospisil H, Murthy PV, Walther R, Sripadi P, and Ummanni R
- Subjects
- Aged, Cell Line, Tumor, Cell Proliferation drug effects, Chromatography, Gas, Cluster Analysis, Humans, Male, Middle Aged, Principal Component Analysis, alpha-Linolenic Acid pharmacology, Biomarkers, Tumor blood, Lipids blood, Prostatic Neoplasms blood, Spectrometry, Mass, Electrospray Ionization, Tandem Mass Spectrometry
- Abstract
Prostate cancer (PCa) is one amongst the most common cancersin western men. Incidence rate ofPCa is on the rise worldwide. The present study deals with theserum lipidome profiling of patients diagnosed with PCa to identify potential new biomarkers. We employed ESI-MS/MS and GC-MS for identification of significantly altered lipids in cancer patient's serum compared to controls. Lipidomic data revealed 24 lipids are significantly altered in cancer patinet's serum (n = 18) compared to normal (n = 18) with no history of PCa. By using hierarchical clustering and principal component analysis (PCA) we could clearly separate cancer patients from control group. Correlation and partition analysis along with Formal Concept Analysis (FCA) have identified that PC (39:6) and FA (22:3) could classify samples with higher certainty. Both the lipids, PC (39:6) and FA (22:3) could influence the cataloging of patients with 100% sensitivity (all 18 control samples are classified correctly) and 77.7% specificity (of 18 tumor samples 4 samples are misclassified) with p-value of 1.612×10-6 in Fischer's exact test. Further, we performed GC-MS to denote fatty acids altered in PCa patients and found that alpha-linolenic acid (ALA) levels are altered in PCa. We also performed an in vitro proliferation assay to determine the effect of ALA in survival of classical human PCa cell lines LNCaP and PC3. We hereby report that the altered lipids PC (39:6) and FA (22:3) offer a new set of biomarkers in addition to the existing diagnostic tests that could significantly improve sensitivity and specificity in PCa diagnosis.
- Published
- 2016
- Full Text
- View/download PDF
41. Identification of New Molecular Entities (NMEs) as Potential Leads against Tuberculosis from Open Source Compound Repository.
- Author
-
Kotapalli SS, Nallam SS, Nadella L, Banerjee T, Rode HB, Mainkar PS, and Ummanni R
- Subjects
- Drug Evaluation, Preclinical methods, Hep G2 Cells, Humans, Mycobacterium bovis growth & development, Mycobacterium smegmatis growth & development, Antitubercular Agents chemistry, Antitubercular Agents pharmacology, Mycobacterium tuberculosis growth & development, Tuberculosis drug therapy
- Abstract
The purpose of this study was to provide a number of diverse and promising early-lead compounds that will feed into the drug discovery pipeline for developing new antitubercular agents. The results from the phenotypic screening of the open-source compound library against Mycobacterium smegmatis and Mycobacterium bovis (BCG) with hit validation against M. tuberculosis (H37Rv) have identified novel potent hit compounds. To determine their druglikeness, a systematic analysis of physicochemical properties of the hit compounds has been performed using cheminformatics tools. The hit molecules were analysed by clustering based on their chemical finger prints and structural similarity determining their chemical diversity. The hit compound library is also filtered for druglikeness based on the physicochemical descriptors following Lipinski filters. The robust filtration of hits followed by secondary screening against BCG, H37Rv and cytotoxicity evaluation has identified 12 compounds with potential against H37Rv (MIC range 0.4 to 12.5 μM). Furthermore in cytotoxicity assays, 12 compounds displayed low cytotoxicity against liver and lung cells providing high therapeutic index > 50. To avoid any variations in activity due to the route of chemical synthesis, the hit compounds were re synthesized independently and confirmed for their potential against H37Rv. Taken together, the hits reported here provides copious potential starting points for generation of new leads eventually adds to drug discovery pipeline against tuberculosis.
- Published
- 2015
- Full Text
- View/download PDF
42. Synthesis and evaluation of novel fluorinated pyrazolo-1,2,3-triazole hybrids as antimycobacterial agents.
- Author
-
Emmadi NR, Bingi C, Kotapalli SS, Ummanni R, Nanubolu JB, and Atmakur K
- Subjects
- Anti-Bacterial Agents chemical synthesis, Cell Line, Tumor, Click Chemistry, Halogenation, Humans, Microbial Sensitivity Tests, Models, Molecular, Mycobacterium Infections, Nontuberculous drug therapy, Pyrazoles chemical synthesis, Structure-Activity Relationship, Triazoles chemical synthesis, Anti-Bacterial Agents chemistry, Anti-Bacterial Agents pharmacology, Mycobacterium smegmatis drug effects, Pyrazoles chemistry, Pyrazoles pharmacology, Triazoles chemistry, Triazoles pharmacology
- Abstract
A library of novel 3-trifluoromethyl pyrazolo-1,2,3-triazole hybrids (5-7) were accomplished starting from 5-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-amine (1) via key intermediate 2-azido-N-(5-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)acetamide (3) through click chemistry approach. Thus obtained compounds in 5-7 series were evaluated for in vitro antimycobacterial activity against Mycobacterium smegmatis (MC(2) 155) and also verified the cytotoxicity. These studies engendered promising lead compounds 5q, 7b and 7c with MIC (μg/mL) values 15.34, 16.18 and 16.60, respectively. Amongst these three compounds, 2-(4-(4-methoxybenzoyl)-1H-1,2,3-triazol-1-yl)-N-(5-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl) acetamide (5q) emerged as the most promising antitubercular agent with lowest cytotoxicity against the A549 cancer cell line. This is the first report to demonstrate the pyrazolo triazole hybrids as potential antimycobacterial agents., (Copyright © 2015 Elsevier Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
43. Prostate cancer-associated autoantibodies in serum against tumor-associated antigens as potential new biomarkers.
- Author
-
Ummanni R, Duscharla D, Barett C, Venz S, Schlomm T, Heinzer H, Walther R, Bokemeyer C, Brümmendorf TH, Murthy PV, and Balabanov S
- Subjects
- Humans, Male, Prostatic Neoplasms diagnosis, Antibodies, Neoplasm blood, Antigens, Neoplasm blood, Autoantibodies blood, Biomarkers, Tumor blood, Prostatic Neoplasms blood
- Abstract
The limitations of the current prostate cancer (PCa) screening tests demands new biomarkers for early diagnosis of PCa. In this study, we aim to investigate serum autoantibody signatures as PCa specific biomarkers. PCa proteins were resolved by 2-DE and then transferred onto polyvinylidene difluoride membrane, which were subsequently incubated with either pooled serum from PCa patients or from normal controls. Mass spectrometry results have identified 18 antigens from 21 different 2-DE spots associated with PCa. Autoantibody response to antigens PRDX2, PRDX6 and ANXA11 in PCa patient's sera was confirmed using recombinant antigens. Further validation with an independent set of PCa patient's sera have shown relatively increased abundance of PRDX6 and ANXA11 antibodies in PCa patients. Formal concept analysis method was applied to assess whether the abundance of these autoantibodies could influence the classification of patients. However, sensitivity of the single antibody to discriminate prostate tumor and healthy controls varies from 70% to 80%, whereas combination of both PRDX6 and ANXA11 antibodies increased sensitivity to 90% for tumors and 100% for healthy controls. Therefore, we hereby report that the detection of these antibodies in PCa patient's serum in combination with the existing non-invasive diagnostic procedures may have significance in PCa diagnosis., Biological Significance: The present study aimed to investigate serum autoantibody signatures as new biomarkers for early diagnosis of prostate cancer (PCa). To investigate serum autoantibodies in patients with PCa, we used proteomics approach based on two-dimensional gel electrophoresis (2-DE) and mass spectrometry. Total tissue proteins extracted from prostate were separated by 2-DE and then transferred onto polyvinylidene difluoride (PVDF) membrane, which were subsequently incubated with either pooled serum from PCa patients or from normal controls with no history for PCa. Proteomic analysis results have identified 18 antigens that showed antibody response specifically to cancer patient's serum. For validation experiments using recombinant antigens, confirmed autoantibody response to three antigens PRDX2, PRDX6 and ANXA11. Further validation using a second independent set of PCa patient's sera has shown relatively increased abundance of PRDX6 and ANXA11 antibodies specifically in PCa patients. Partition analysis of patients based on abundance of autoantibodies highlighted a combination of both PRDX6 and ANXA11 antibodies in serum with 90% sensitivity in case of tumors and 100% in case of healthy controls. Therefore, we hereby report that the detection of these antibodies in PCa patient's serum in combination with known markers may have significance in diagnosis of PCa with further validation in larger cohort of samples., (Copyright © 2015 Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
44. Synthesis and biological screening of 2'-aryl/benzyl-2-aryl-4-methyl-4',5-bithiazolyls as possible anti-tubercular and antimicrobial agents.
- Author
-
Abhale YK, Sasane AV, Chavan AP, Deshmukh KK, Kotapalli SS, Ummanni R, Sayyad SF, and Mhaske PC
- Subjects
- Anti-Bacterial Agents chemical synthesis, Anti-Bacterial Agents chemistry, Bacillus subtilis drug effects, Dose-Response Relationship, Drug, Escherichia coli drug effects, Microbial Sensitivity Tests, Molecular Structure, Mycobacterium smegmatis drug effects, Proteus vulgaris drug effects, Staphylococcus aureus drug effects, Structure-Activity Relationship, Thiazoles chemical synthesis, Thiazoles chemistry, Anti-Bacterial Agents pharmacology, Thiazoles pharmacology
- Abstract
A series of 2'-aryl/benzyl-2-aryl-4-methyl-4',5-bithiazolyl derivatives, 25-64 were synthesized and evaluated for inhibitory activity against Mycobacterium smegmatis MC(2) 155 strain and antimicrobial activities against four pathogenic bacteria Bacillus subtilis, Staphylococcus aureus, Escherichia coli and Proteus vulgaris. Among them, compounds 40, 49, 50, and 54 exhibited moderate to good inhibition on the growth of the bacteria Mycobacterium smegmatis at the concentration of 30 μM. Compounds 26, 40, 44, 54 and 56 exhibited moderate to good antibacterial activity. Compound 5-(2'-(4-fluorobenzyl)thiazol-4'-yl)-2-(4-fluorophenyl)-4-methyl-thiazole (54) exhibited both antitubercular as well as antimicrobial activity against all tested strains., (Copyright © 2015 Elsevier Masson SAS. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
45. Synthesis, in vitro anticancer and antimycobacterial evaluation of new 5-(2,5-dimethoxyphenyl)-1,3,4-thiadiazole-2-amino derivatives.
- Author
-
Polkam N, Rayam P, Anireddy JS, Yennam S, Anantaraju HS, Dharmarajan S, Perumal Y, Kotapalli SS, Ummanni R, and Balasubramanian S
- Subjects
- Anti-Bacterial Agents chemical synthesis, Anti-Bacterial Agents chemistry, Antineoplastic Agents chemical synthesis, Antineoplastic Agents chemistry, Cell Line, Tumor, Cell Proliferation drug effects, Crystallography, X-Ray, Dose-Response Relationship, Drug, Drug Screening Assays, Antitumor, HEK293 Cells, HT29 Cells, Humans, Microbial Sensitivity Tests, Models, Molecular, Molecular Structure, Structure-Activity Relationship, Anti-Bacterial Agents pharmacology, Antineoplastic Agents pharmacology, Mycobacterium smegmatis drug effects
- Abstract
A series of 2,5-disubstituted-1,3,4-thiadiazole derivatives 5a-5l, 7a-7e and 9 have been synthesised and screened for in vitro antimycobacterial activity against Mycobacterium smegmatis MC-155. In addition these compounds have also been screened for cytotoxic activity against cancer cell lines HT-29, MDA-MB-231 by MTT colorimetric assay. The compounds are well characterized by spectral analysis viz. (1)H NMR, (13)C NMR, FT-IR, mass and HRMS. Screening results indicate that compounds 5g, 7a possess good antitubercular activity with MIC value 65.74 and 40.86, respectively, compounds 5g, 7a, 7b, 7d, 7e and 9 displayed promising cytotoxic activity against the cell lines tested. 5g and 7a stand out to be potent antimycobacterial and anticancer agents among the tested series. Further the title compounds were also tested on human normal cells HEK293T and are found to be safer with lesser cytotoxicity. It is interesting to observe that compound 5g has come out to be safer, potent anticancer and antimycobacterial agent., (Copyright © 2015 Elsevier Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
46. Investigation of podophyllotoxin esters as potential anticancer agents: synthesis, biological studies and tubulin inhibition properties.
- Author
-
Shareef MA, Duscharla D, Ramasatyaveni G, Dhoke NR, Das A, Ummanni R, and Srivastava AK
- Subjects
- Antineoplastic Agents chemical synthesis, Antineoplastic Agents chemistry, Apoptosis drug effects, Cell Line, Tumor, Cell Proliferation drug effects, Dose-Response Relationship, Drug, Drug Screening Assays, Antitumor, Esters chemical synthesis, Esters chemistry, Hep G2 Cells, Humans, MCF-7 Cells, Molecular Structure, Podophyllotoxin analogs & derivatives, Podophyllotoxin chemistry, Structure-Activity Relationship, Tubulin Modulators chemical synthesis, Tubulin Modulators chemistry, Antineoplastic Agents pharmacology, Esters pharmacology, Podophyllotoxin pharmacology, Tubulin metabolism, Tubulin Modulators pharmacology
- Abstract
A series of fifteen podophyllotoxin derived esters have been synthesized and their anti-cancer properties have been evaluated against A549 (lung cancer), DU-145 (prostate cancer), HepG2 (liver cancer), HeLa (cervical cancer) and MCF-7 (breast cancer) cell lines. Five compounds of the series 8a, 8g-h, 8m and 8o showed IC50 values in the range of 0.71-10.94 μM. Among compounds, 8g and 8h showed significant cytotoxicity towards all the types of cancer studied. Cell cycle analysis revealed that the compounds 8a, 8m and 8o inhibit proliferation by cell cycle arrest. Also Hoechst-positive nucleus indicating apoptosis of these cells was observed in presence of 8g-h. Further studies revealed that these compounds inhibit tubulin polymerization and leads to the inactivation of AKT/PKB that are known to play an important role in the proliferation of cancer cells., (Copyright © 2014 Elsevier Masson SAS. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
47. Fluvastatin mediated breast cancer cell death: a proteomic approach to identify differentially regulated proteins in MDA-MB-231 cells.
- Author
-
Kanugula AK, Dhople VM, Völker U, Ummanni R, and Kotamraju S
- Subjects
- Acyl Coenzyme A metabolism, Breast Neoplasms, Caspase 3 chemistry, Caspase 3 metabolism, Cell Line, Tumor, Chromatography, High Pressure Liquid, Epithelial-Mesenchymal Transition drug effects, Female, Fluvastatin, Humans, Metabolic Networks and Pathways, Mevalonic Acid pharmacology, Mitogen-Activated Protein Kinase 1 metabolism, Tandem Mass Spectrometry, Vimentin metabolism, Anticholesteremic Agents toxicity, Apoptosis drug effects, Electrophoresis, Gel, Two-Dimensional, Fatty Acids, Monounsaturated toxicity, Indoles toxicity, Proteome analysis
- Abstract
Statins are increasingly being recognized as anti-cancer agents against various cancers including breast cancer. To understand the molecular pathways targeted by fluvastatin and its differential sensitivity against metastatic breast cancer cells, we analyzed protein alterations in MDA-MB-231 cells treated with fluvastatin using 2-DE in combination with LC-MS/MS. Results revealed dys-regulation of 39 protein spots corresponding to 35 different proteins. To determine the relevance of altered protein profiles with breast cancer cell death, we mapped these proteins to major pathways involved in the regulation of cell-to-cell signaling and interaction, cell cycle, Rho GDI and proteasomal pathways using IPA analysis. Highly interconnected sub networks showed that vimentin and ERK1/2 proteins play a central role in controlling the expression of altered proteins. Fluvastatin treatment caused proteolysis of vimentin, a marker of epithelial to mesenchymal transition. This effect of fluvastatin was reversed in the presence of mevalonate, a downstream product of HMG-CoA and caspase-3 inhibitor. Interestingly, fluvastatin neither caused an appreciable cell death nor did modulate vimentin expression in normal mammary epithelial cells. In conclusion, fluvastatin alters levels of cytoskeletal proteins, primarily targeting vimentin through increased caspase-3- mediated proteolysis, thereby suggesting a role for vimentin in statin-induced breast cancer cell death.
- Published
- 2014
- Full Text
- View/download PDF
48. Design, synthesis and anti-mycobacterial activity of 1,2,3,5-tetrasubstituted pyrrolyl-N-acetic acid derivatives.
- Author
-
Pagadala LR, Mukkara LD, Singireddi S, Singh A, Thummaluru VR, Jagarlamudi PS, Guttala RS, Perumal Y, Dharmarajan S, Upadhyayula SM, Ummanni R, Basireddy VS, and Ravirala N
- Subjects
- Acetates chemical synthesis, Acetates chemistry, Anti-Bacterial Agents chemical synthesis, Anti-Bacterial Agents chemistry, Dose-Response Relationship, Drug, Microbial Sensitivity Tests, Molecular Structure, Pyrroles chemical synthesis, Pyrroles chemistry, Structure-Activity Relationship, Acetates pharmacology, Anti-Bacterial Agents pharmacology, Drug Design, Mycobacterium tuberculosis drug effects, Pyrroles pharmacology
- Abstract
A novel synthesis of highly substituted pyrrole-N-acetic derivatives is described through the coupling of 1,4-diketones with amino acids following Paal-Knorr's approach. These pyrrole-N-acetic acid derivatives are found to exhibit potent anti-mycobacterial activity against Mycobacterium smegmatis and Mycobacterium tuberculosis strain H37Rv. In particular, 5n, 5q &5r are found to display excellent anti-mycobacterial activity against M. tuberculosis strain H37Rv with MIC values in the range of 2.97 μM. Conversely, these compounds showed low cytotoxicity (selectivity index: >16.83) against HEK-293T cell line., (Copyright © 2014 Elsevier Masson SAS. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
49. Statin-induced inhibition of breast cancer proliferation and invasion involves attenuation of iron transport: intermediacy of nitric oxide and antioxidant defence mechanisms.
- Author
-
Kanugula AK, Gollavilli PN, Vasamsetti SB, Karnewar S, Gopoju R, Ummanni R, and Kotamraju S
- Subjects
- Antigens, CD genetics, Antigens, CD metabolism, Apoptosis, Biological Transport drug effects, Cell Line, Tumor, Down-Regulation drug effects, Drug Screening Assays, Antitumor, Female, Fluvastatin, Gene Expression Regulation, Neoplastic drug effects, Humans, Hydrogen Peroxide metabolism, Mevalonic Acid pharmacology, Nitric Oxide Synthase Type II metabolism, Receptors, Transferrin genetics, Receptors, Transferrin metabolism, Superoxide Dismutase genetics, Superoxide Dismutase metabolism, Transcription, Genetic, Triple Negative Breast Neoplasms, Antineoplastic Agents pharmacology, Antioxidants metabolism, Cell Proliferation drug effects, Fatty Acids, Monounsaturated pharmacology, Indoles pharmacology, Iron metabolism, Nitric Oxide metabolism, Simvastatin pharmacology
- Abstract
Accumulating evidence from in vitro, in vivo, clinical and epidemiological studies shows promising results for the use of statins against many cancers including breast carcinoma. However, the molecular mechanisms responsible for the anti-proliferative and anti-invasive properties of statins still remain elusive. In this study, we investigated the involvement of nitric oxide, iron homeostasis and antioxidant defence mechanisms in mediating the anti-proliferative and anti-invasive properties of hydrophobic statins in MDA-MB-231, MDA-MB-453 and BT-549 metastatic triple negative breast cancer cells. Fluvastatin and simvastatin significantly increased cytotoxicity which was reversed with mevalonate. Interestingly, fluvastatin downregulated transferrin receptor (TfR1), with a concomitant depletion of intracellular iron levels in these cells. Statin-induced effects were mimicked by geranylgeranyl transferase inhibitor (GGTI-298) but not farnesyl transferase inhibitor (FTI-277). Further, it was observed that TfR1 downregulation is mediated by increased nitric oxide levels via inducible nitric oxide synthase (iNOS) expression. NOS inhibitors (asymmetric dimethylarginine and 1400W) counteracted and sepiapterin, a precursor of tetrahydrobiopterin, exacerbated statin-induced depletion of intracellular iron levels. Notably, fluvastatin increased manganese superoxide dismutase (by repressing the transcription factor DNA damage-binding protein 2), catalase and glutathione which, in turn, diminished H2 O2 levels. Fluvastatin-induced downregulation of TfR1, matrix metalloproteinase-2, -9 and inhibition of invasion were reversed in the presence of aminotriazole, a specific inhibitor of catalase. Finally, we conclude that fluvastatin, by altering iron homeostasis, nitric oxide generation and antioxidant defence mechanisms, induces triple negative breast cancer cell death., (© 2014 FEBS.)
- Published
- 2014
- Full Text
- View/download PDF
50. Oxazolidinone derivatives: cytoxazone-linezolid hybrids induces apoptosis and senescence in DU145 prostate cancer cells.
- Author
-
Naresh A, Venkateswara Rao M, Kotapalli SS, Ummanni R, and Venkateswara Rao B
- Subjects
- Antineoplastic Agents chemical synthesis, Caspase 3 metabolism, Caspase 9 metabolism, Cell Line, Tumor, Humans, Linezolid, Male, Membrane Potential, Mitochondrial drug effects, Acetamides chemistry, Antineoplastic Agents chemistry, Antineoplastic Agents pharmacology, Apoptosis drug effects, Cellular Senescence drug effects, Oxazoles chemistry, Oxazolidinones chemistry, Prostatic Neoplasms pathology
- Abstract
In this study, we report the synthesis of novel oxazolidinone derivatives derived from linezolid 3 having p-methoxyphenyl group at C-4 position. In vitro evaluation for their anticancer activity toward cultured A549, DU145, HELA, and MCF7 were carried out. The series of compounds prepared displayed wide range of cytotoxicity in MTT assays (10-70 μM) across the cell lines tested. Of the all tested compounds 16 and 17 displayed good anticancer potential against A549 (lung) and DU145 (prostate) cancer cells. Further, to determine their anticancer potential, in the present study we have assessed effect of 17 on DU145 cells growth in in vitro assays. The results clearly demonstrated that the exposure of DU145 cells to 17 inhibits cell proliferation and induces apoptosis by activation of caspase-3 and -9. Long term exposure of DU145 cells to 17 induced cellular senescence confirmed by senescence marker β-galactosidase staining of cells on post exposure to 17. The results from this current report support that the oxazolidinone derivatives with ethyl and acryl substitutions showed promising anticancer activity which will be helpful to develop further novel anticancer agents with better therapeutic potential., (Copyright © 2014 Elsevier Masson SAS. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.